Bone Marrow Failure Syndromes, Histiocytosis, Immunodeficiencies, Leukemia, Lymphoma
Conditions
Keywords
Allogeneic Stem Cell Transplant, Unrelated donor, Cord blood donor
Brief summary
Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree of engraftment in patients with selected malignant and non malignant disorders.
Detailed description
This is a non-randomized study to determine the tolerability and degree of engraftment of unrelated matched donor allogeneic stem cell transplantation with either myeloablative or reduced intensity conditioning in patients with selected malignant and non malignant disorders. Patients will receive one of either full intensity or reduced intensity regimen based on the patient's disease status, organ function and performance and determined by the PI.
Interventions
PROCEDUREUDAlloSCT
unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
OTHERTherapy
Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
Sponsors
Columbia University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 55 Years
Healthy volunteers
No
Inclusion criteria
* Adequate renal function defined as: serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR \> 40 ml/min/m2 or \> 40 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range. * Adequate liver function defined as: total bilirubin \< 2.5 x normal; or SGOT (AST) or SGPT (ALT) \< 5.0 x normal. * Adequate cardiac function defined as: shortening fraction of \> 25% by echocardiogram, or ejection fraction of \> 40% by radionuclide angiogram or echocardiogram. * Adequate pulmonary function defined as: DLCO \> 35% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% in room air. * Diseases: * CML (CP, AP or BC) * AML/MDS/JCML * ALL * Lymphoma (Hodgkin's and non-Hodgkin's) * Non-malignant disorders * Bone Marrow Failure Syndromes: Patients with the following diagnoses are eligible: * Severe Aplastic Anemia: * Fanconi Anemia * Severe Congenital Neutropenia (Kostmann's Syndrome) * Amegakaryocytic Thrombocytopenia * Diamond-Blackfan Anemia * Infantile Osteopetrosis * Schwachman-Diamond Syndrome * Dyskeratosis Congenita * Other bone marrow failure syndromes at discretion of Principal Investigator * Immunodeficiencies: * SCIDS, all subtypes * Combined Immunodeficiency Syndrome * Wiskott-Aldrich syndrome * Chronic Granulomatous Disease * Chediak-Higashi Syndrome * Leukocyte Adhesion Deficiency * Other immunodeficiencies at discretion of Principal Investigator * Inborn Errors of Metabolism (IEOM): * Transplant is recommended for the following disorders: Hurler syndrome (L-iduronidase deficiency, MPS-I), Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency, MP VI), Sly syndrome (glucuronidase deficiency, MPS-VII), Globoid cell Leukodystrophy (galactocerebrosidasedeficiency), Metachromatic leukodystrophy (arylsulfatase A deficiency), Childhood-onset X-linked adrenoleukodystrophy (X-ALD), Fucosidosis (fucosidase deficiency), Mannosidosis, Aspartylglucosaminuria, Niemann-Pick Disease Type B (acid sphingomyelinase deficiency), Gaucher disease (glucocerebrosidase deficiency) Type I (non neuropathic), Other diagnoses may be considered at the discretion of the Principal Investigator * For X-ALD patients greater than 5 years of age, IQ \> 80 is required. For other patients greater than 5 years of age, IQ \> 70 is required. * For patients less than 5 years of age, the developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g. mechanical ventilation) would not be predicted to be required in the year following transplantation. * Histiocytosis: * Hemophagocytic Lymphohistiocytosis (HLH) * Familial Erythrophagocytic Lymphohistiocytosis * Langerhans Cell Histiocytosis * Malignant Histiocytosis * Other Malignant and non-malignant diseases: Other malignant and non-malignant diseases not listed above may be eligible if deemed appropriate by the Principal Investigator.
Exclusion criteria
* Women who are pregnant and/or breast feeding are ineligible
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of toxicity related to myeloablative therapy | Up to 10 years from start of study | To determine the safety and toxicity of myeloablative therapy (TBI + Melphalan) and unrelated donor alloSCT in selected patients with malignant and non-malignant disorders. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of toxicity related to reduced intensity therapy | Up to 10 years from start of study | To determine the safety and toxicity of reduced intensity therapy (Fludarabine, Busulfan, and Alemtuzumab (FBA) and unrelated donor alloSCT in selected patients with malignant and non malignant disorders |
| Percentage of donor chimerism | Up to 10 years from start of study | To quantitate the percentage of donor chimerism following both myeloablative and reduced intensity conditioning and unrelated donor alloSCT in selected patients with malignant and non-malignant disorders. |
| Prevalence of progression free survival | Up to 10 years from start of study | To estimate the progression free survival (PFS), if applicable, event free survival (EFS) and overall survival (OS) following unrelated donor alloSCT in selected patients with malignant and non malignant disorders. |
Countries
United States
Outcome results
None listed